Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Maxime Dougados; Christina Charles-Schoeman; Zoltán Szekanecz; Jon T. Giles; Steven R. Ytterberg; Deepak L. Bhatt; Gary G. Koch; Ivana Vranic; Joseph Wu; Cunshan Wang; Kenneth Kwok; Sujatha Menon; Carol A. Connell; Arne Yndestad; Jose L. Rivas; Maya H. Buch

doi:10.1136/ard-2022-223406

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, Jon T. Giles, Steven R. Ytterberg, Deepak L. Bhatt, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Carol A. Connell, Arne Yndestad, Jose L. Rivas, Maya H. Buch

Rheumatology

Research output: Contribution to journal › Letter › peer-review

Abstract

The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2

Original language	English (US)
Pages (from-to)	575-577
Number of pages	3
Journal	Annals of the rheumatic diseases
Volume	82
Issue number	4
DOIs	https://doi.org/10.1136/ard-2022-223406
State	Published - Apr 1 2023

Keywords

Antirheumatic Agents
Arthritis, Rheumatoid
Cardiovascular Diseases

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1136/ard-2022-223406

Cite this

Dougados, M., Charles-Schoeman, C., Szekanecz, Z., Giles, J. T., Ytterberg, S. R., Bhatt, D. L., Koch, G. G., Vranic, I., Wu, J., Wang, C., Kwok, K., Menon, S., Connell, C. A., Yndestad, A., Rivas, J. L., & Buch, M. H. (2023). Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Annals of the rheumatic diseases, 82(4), 575-577. https://doi.org/10.1136/ard-2022-223406

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. / Dougados, Maxime; Charles-Schoeman, Christina; Szekanecz, Zoltán et al.
In: Annals of the rheumatic diseases, Vol. 82, No. 4, 01.04.2023, p. 575-577.

Research output: Contribution to journal › Letter › peer-review

Dougados, M, Charles-Schoeman, C, Szekanecz, Z, Giles, JT, Ytterberg, SR, Bhatt, DL, Koch, GG, Vranic, I, Wu, J, Wang, C, Kwok, K, Menon, S, Connell, CA, Yndestad, A, Rivas, JL & Buch, MH 2023, 'Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme', Annals of the rheumatic diseases, vol. 82, no. 4, pp. 575-577. https://doi.org/10.1136/ard-2022-223406

@article{46c9ecf632124fed9b14102362460b6f,

title = "Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme",

abstract = "The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2",

keywords = "Antirheumatic Agents, Arthritis, Rheumatoid, Cardiovascular Diseases",

author = "Maxime Dougados and Christina Charles-Schoeman and Zolt{\'a}n Szekanecz and Giles, {Jon T.} and Ytterberg, {Steven R.} and Bhatt, {Deepak L.} and Koch, {Gary G.} and Ivana Vranic and Joseph Wu and Cunshan Wang and Kenneth Kwok and Sujatha Menon and Connell, {Carol A.} and Arne Yndestad and Rivas, {Jose L.} and Buch, {Maya H.}",

note = "Funding Information: This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Julia King, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer, New York, New York, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022;175:1298–304). ",

year = "2023",

month = apr,

day = "1",

doi = "10.1136/ard-2022-223406",

language = "English (US)",

volume = "82",

pages = "575--577",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

AU - Dougados, Maxime

AU - Charles-Schoeman, Christina

AU - Szekanecz, Zoltán

AU - Giles, Jon T.

AU - Ytterberg, Steven R.

AU - Bhatt, Deepak L.

AU - Koch, Gary G.

AU - Vranic, Ivana

AU - Wu, Joseph

AU - Wang, Cunshan

AU - Kwok, Kenneth

AU - Menon, Sujatha

AU - Connell, Carol A.

AU - Yndestad, Arne

AU - Rivas, Jose L.

AU - Buch, Maya H.

N1 - Funding Information: This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Julia King, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer, New York, New York, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022;175:1298–304).

PY - 2023/4/1

Y1 - 2023/4/1

N2 - The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2

AB - The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Cardiovascular Diseases

UR - http://www.scopus.com/inward/record.url?scp=85148667393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148667393&partnerID=8YFLogxK

U2 - 10.1136/ard-2022-223406

DO - 10.1136/ard-2022-223406

M3 - Letter

C2 - 36720582

AN - SCOPUS:85148667393

SN - 0003-4967

VL - 82

SP - 575

EP - 577

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 4

ER -

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this